Aziz, Aamir A. https://orcid.org/0000-0002-3657-4861
Khanani, Arshad M. https://orcid.org/0000-0001-8928-5599
Khan, Hannah
Lauer, Eileen
Khanani, Ibrahim
Mojumder, Ohidul
Khanani, Zoha A.
Khan, Huma
Gahn, Greggory M.
Graff, J. Taylor
Abbey, Ashkan M.
Almeida, David R. P.
Barakat, Mark R. https://orcid.org/0000-0002-1328-6314
Corradetti, Giulia https://orcid.org/0000-0001-9213-5575
Graff, Jordan M.
Haug, Sara J.
Nielsen, Jared S.
Sheth, Veeral S.
Sadda, SriniVas R. https://orcid.org/0000-0002-4939-3306
Hadas, Ilan
Benyamini, Gidi
Nahen, Kester
Mohan, Nishant
Article History
Received: 22 May 2024
Revised: 8 November 2024
Accepted: 29 November 2024
First Online: 11 December 2024
Competing interests
: AAA reports other from REGENXBIO INC, outside the submitted work; paid summer internship. AMK reports personal fees from AbbVie, grants and personal fees from Adverum Biotechnologies, personal fees from Alcon, personal fees from Amgen, personal fees from Annexin, personal fees from Annexon, grants and personal fees from Apellis Pharmaceuticals, grants, financial interest, and personal fees from Aviceda Therapeutics, personal fees from Beacon Therapeutics, personal fees from Clearside Biomedical, personal fees from Complement Therapeutics, grants and personal fees from Genentech, grants and personal fees from Gyroscope Therapeutics, personal fees from i-Lumen Scientific, grants and personal fees from Iveric Bio, grants and personal fees from Janssen Pharmaceuticals, grants from personal fees from Kodiak Sciences, personal fees from Kriya Therapeutics, personal fees from Nanoscope, personal fees from Novartis, grants and personal fees from Ocular Therapeutix, grants, financial interest, and personal fees from Oculis, personal fees from Ocuphire, grants and personal fees from OcuTerra, personal fees from Olive Biopharma, grants, financial interest and personal fees from Opthea, grants and personal fees from Oxular, grants and personal fees from Oxurion, personal fees from Perfuse, personal fees from Ray Therapeutics, financial interest and personal fees from Recens Medical, personal fees from Regeneron Pharmaceuticals, grants, financial interest, and personal fees from Regenexbio, personal fees from Revive, financial interest and personal fees from RevOpsis, grants and personal fees from Roche, personal fees from Sanofi, personal fees from Stealth BioTherapeutics, personal fees from Thea Pharma, grants and personal fees from Unity Biotechnology, grants from personal fees from Vanotech, financial interest and personal fees from Vial, grants from Aviceda, grants from Alexion, grants from 4DMT, grants from Eyepoint, grants from Exegenesis, grants from Neurotech, financial interest from PolyPhotonix. Ms. HK reports other from Genentech, outside the submitted work; paid summer internship. EL reports employment with Notal Vision. Mr. Khanani has nothing to disclose. OM has nothing to disclose. Ms. Khanani has nothing to disclose. Ms. Khan has nothing to disclose. GMG reports personal fees from REGENXBIO. Mr. Graff has nothing to disclose. AMA reports personal fees from Genentech, outside the submitted work. DRPA reports personal fees and other from ACELYRIN, personal fees from ALCON, personal tees and other from ALIMERA SCIENCES, personal fees and other from ALLERGAN/ABBVIE, personal fees from BAUSCH + LOMB, personal fees from BAYER, personal fees and other from BOEHRINGER INGELHEIM, personal fees, non-financial support and other from CITRUS THERAPEUTICS, personal fees, non-financial support and other from CLINICAL TRIALS NETWORK, personal fees and other from EYEPOINT PHARMACEUTICALS, personal fees and other from GENENTECH, personal fees and other from GYROSCOPE THERAPEUTICS, personal fees and other from NOVARTIS, personal fees from OCUGEN, personal fees and other from OPTHEA, personal fees from REGENERON, personal fees and other from REGENXBIO, personal fees and other from ROCHE, personal fees and other from SAMSARA VISION, personal fees from SPHERIX CONSULTING GROUP, outside the submitted work. MRB reports personal fees from Alcon, personal fees from Allegro, personal fees from Allergan, personal fees from Alimera, personal fees from Bausch & Lomb, grants and personal fees from Clearside Biomedical, grants and personal fees from EyePoint Pharmaceuticals, grants and personal fees from Kodiak Sciences, grants and personal fees from Genentech, grants and personal fees from Novartis, other from NeuBase, grants and personal fees from Ocular Therapeutix, grants and other from Oxurion, grants and personal fees from RegenxBio, grants and personal fees from Adverum Biotechnologies, personal fees from Regeneron, grants and personal fees from CalciMedica, personal fees from Palatin Technologies, personal fees from AbbVie Inc, grants from Annexon Biosciences, personal fees from Apellis, personal fees from Arctic Vision, personal fees from Biogen, personal fees from Coherus Biosciences, grants from Gemini Therapetucis, grants from Gyroscope Therapeutics, grants from Oxular, grants from Oculis, grants and personal fees from Opthea, personal fees from Outlook Therapeutics, grants from ReNeuron, personal fees and other from RevOpsis Therapeutics, grants from Ribomic, personal fees from Roche, grants and personal fees from Stealth Biotherapeutics, grants from Unity Biotechnology, personal fees from Astellas, personal fees from Cencora, personal fees from Biocryst, personal fees from Celltrion, grants from EyeBio, grants and personal fees from Janssen, grants from Kanghong/Vanotech, personal fees from Neurotech, grants from Perfuse, outside the submitted work. GC reports personal fees from Nidek. Dr Graff reports grants and personal fees from Genentech, grants and personal fees from Roche, grants and personal fees from RegenxBio, grants from Ocular Therapeutix, grants from Kyowa Kirin, personal fees from Hi-Health, personal fees from Alimera, personal fees from Regeneron, personal fees from IvericBio. SJH has nothing to disclose. JSN reports grants from AbbVie, personal fees from Alcon, grants from Alexion, grants and personal fees from Apellis, grants and personal fees from Astellas, grants from Bayer, personal fees from Bausch and Lomb, grants from Clearside Biomedical, grants and personal fees from Genentech/Roche, grants from Gyroscope Therapeutics, grants from Novartis, grants from NovoNordisk, grants from Ocular Therapeutics, grants and personal fees from Regeneron, grants from RegenexBio. VSS reports grants and personal fees from Genentech, grants and personal fees from Alimera, grants and personal fees from Novartis, grants and personal fees from Iveric Bio, grants and personal fees from Regeneron, grants from Gyroscope, grants from RegenXBio, grants from Chengdu Kanghong, grants from NGM Biopharmaceuticals, grants from SamChungDang, grants from Sandoz, grants from Alkahest, grants and personal fees from Apellis, grants from EyePoint, grants from Oxurion, grants from 4D Molecular Therapeutics, grants from Ashvattha Therapeutics, grants from NGM Biopharmaceuticals, grants from Olix Pharmaceuticals, grants from Janssen, from OcuTerra, outside the submitted work. SRS reports personal fees from Apellis, personal fees from Amgen, personal fees from Abbvie/Allergan, personal fees from Alexion, personal fees from Samsung Bioepis, personal fees from Biogen, personal fees from Boerhinger Ingelheim, personal fees from Astellas/IvericBio, personal fees from Novartis, personal fees from Roche/Genentech, personal fees from Bayer, personal fees from Regeneron, personal fees from Pfizer, personal fees from Nanoscope, personal fees from Jannsen, personal fees fees and research instruments from iCare, personal fees and research instruments from Optos, personal fees fees and research instruments from Heidelberg, personal fees from NotalVision, personal fees fees and research instruments from Topcon, personal fees from Eyepoint, personal fees from Character, personal fees from Ocular Therapeutics, personal fees from Neurotech, personal fees from Nidek, personal fees from RegenxBio, research instruments from Carl Zeiss Meditec, personal fees and research instruments from Nidek. IH reports employment with Notal Vision. Mr Benyamini reports employment with Notal Vision. KN reports employment with Notal Vision. NM reports employment with Notal Vision.